Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma (NCT06970145) | Clinical Trial Compass
RecruitingPhase 1/2
Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
China57 participantsStarted 2025-04-25
Plain-language summary
Primary Aim:
To assess the objective remission rate (ORR) of patients with recurrent craniopharyngiomas treated with anlotinib .
Secondary Aims:
1. To assess progression-free survival (PFS) and overall survival (OS) of patients with recurrent craniopharyngiomas treated with anlotinib.
2. To analyze the disease control rate (DCR) of the anlotinib treatment regimen in patients with recurrent craniopharyngiomas, including the proportion of patients in complete remission, partial remission and stable disease.
3. Monitor and evaluate the safety of anlotinib, especially the occurrence of drug-related adverse events (AEs) .
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 18-75 years old, regardless of gender
✓. recurrent craniopharyngioma (recurrence after total resection or regrowth of residual tumor) confirmed by pathology and imaging data
✓. predominantly cystic or solid recurrence of the tumor
✓. measurable lesions (according to the RECIST criteria)